Literature DB >> 12388640

Pharmacological profile of the novel inotropic agent (E,Z)-3-((2-aminoethoxy)imino)androstane-6,17-dione hydrochloride (PST2744).

R Micheletti1, G G Mattera, M Rocchetti, A Schiavone, M F Loi, A Zaza, R J P Gagnol, S De Munari, P Melloni, P Carminati, G Bianchi, P Ferrari.   

Abstract

The novel Na(+)/K(+)-ATPase inhibitor (E,Z)-3-((2-aminoethoxy)imino)androstane-6,17-dione hydrochloride (PST2744) was characterized for its inotropic and toxic properties. Inhibition potency on dog kidney Na(+)/K(+)-ATPase was comparable (0.43 microM) to that of digoxin (0.45 microM). PST2744 concentration-dependently increased force of contraction in guinea pig atria and twitch amplitude in isolated guinea pig myocytes; in the latter, aftercontractions developed significantly less than with digoxin. Intravenous infusion of 0.2 mg/kg/min PST2744 in anesthetized guinea pigs exerted an immediate and long-lasting inotropic effect (ED(80) of 1.89 +/- 0.37 mg/kg) without causing lethal arrhythmias up to a cumulative dose of 18 mg/kg. Conversely, an equieffective infusion of digoxin (0.016 mg/kg/min; ED(80) of 0.32 mg/kg) caused lethal arrhythmias at a cumulative dose of 0.81 mg/kg. At a higher rate (0.4 mg/kg/min), PST2744 induced lethal arrhythmias, with a lethal dose/ED(80) ratio significantly greater than digoxin (20.2 +/- 6.3 versus 3.23 +/- 0.55, p < 0.05). Decay of the inotropic effect (t(1/2), min) was significantly faster for PST2744 (6.0 +/- 0.39) than for digoxin (18.3 +/- 4.5, p < 0.05). In anesthetized dogs, PST2744 dose-dependently increased maximum velocity of pressure rise (+dP/dt(max)) in the range 32 to 500 microg/kg i.v. and was safer than digoxin. In conscious dogs with a healed myocardial infarction, PST2744 significantly increased resting values of +dP/dt(max), left ventricular pressure, and SPB, and increased +dP/dt(max) throughout treadmill exercise while reverting the increase in left ventricular end diastolic pressure seen in control animals. Digoxin significantly decreased basal heart rate, while not affecting the hemodynamic response to exercise. Thus, PST2744 represents a new class of Na(+)/K(+)-ATPase inhibitors endowed with inotropic activity comparable with that of digitalis but having greater safety.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12388640     DOI: 10.1124/jpet.102.038331

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  11 in total

1.  Binding of cardiotonic steroids to Na+,K+-ATPase in the E2P state.

Authors:  Ryuta Kanai; Flemming Cornelius; Haruo Ogawa; Kanna Motoyama; Bente Vilsen; Chikashi Toyoshima
Journal:  Proc Natl Acad Sci U S A       Date:  2021-01-07       Impact factor: 11.205

2.  Acute heart failure with low cardiac output: can we develop a short-term inotropic agent that does not increase adverse events?

Authors:  Umberto Campia; Savina Nodari; Mihai Gheorghiade
Journal:  Curr Heart Fail Rep       Date:  2010-09

Review 3.  Novel drug targets in clinical development for heart failure.

Authors:  Melvin George; Muthukumar Rajaram; Elangovan Shanmugam; Thangavel Mahalingam VijayaKumar
Journal:  Eur J Clin Pharmacol       Date:  2014-04-09       Impact factor: 2.953

Review 4.  Istaroxime, a first in class new chemical entity exhibiting SERCA-2 activation and Na-K-ATPase inhibition: a new promising treatment for acute heart failure syndromes?

Authors:  Hashim Khan; Marco Metra; John E A Blair; Mark Vogel; Matthew E Harinstein; Gerasimos S Filippatos; Hani N Sabbah; Herve Porchet; Giovanni Valentini; Mihai Gheorghiade
Journal:  Heart Fail Rev       Date:  2009-02-24       Impact factor: 4.214

Review 5.  Novel pharmacologic therapies in development for acute decompensated heart failure.

Authors:  Justin A Ezekowitz
Journal:  Curr Cardiol Rep       Date:  2013-02       Impact factor: 2.931

6.  Istaroxime stimulates SERCA2a and accelerates calcium cycling in heart failure by relieving phospholamban inhibition.

Authors:  Mara Ferrandi; Paolo Barassi; Francesco Tadini-Buoninsegni; Gianluca Bartolommei; Isabella Molinari; Maria Grazia Tripodi; Cristina Reina; Maria Rosa Moncelli; Giuseppe Bianchi; Patrizia Ferrari
Journal:  Br J Pharmacol       Date:  2013-08       Impact factor: 8.739

7.  Functional characterization and anti-cancer action of the clinical phase II cardiac Na+/K+ ATPase inhibitor istaroxime: in vitro and in vivo properties and cross talk with the membrane androgen receptor.

Authors:  Konstantinos Alevizopoulos; Konstantinos Dimas; Natalia Papadopoulou; Eva-Maria Schmidt; Anna Tsapara; Saad Alkahtani; Sabina Honisch; Kyriakos C Prousis; Saud Alarifi; Theodora Calogeropoulou; Florian Lang; Christos Stournaras
Journal:  Oncotarget       Date:  2016-04-26

Review 8.  Drug Interactions With the Ca2+-ATPase From Sarco(Endo)Plasmic Reticulum (SERCA).

Authors:  Francesco Tadini-Buoninsegni; Serena Smeazzetto; Roberta Gualdani; Maria Rosa Moncelli
Journal:  Front Mol Biosci       Date:  2018-04-11

Review 9.  Targeting Ca2 + Handling Proteins for the Treatment of Heart Failure and Arrhythmias.

Authors:  Alexandra Njegic; Claire Wilson; Elizabeth J Cartwright
Journal:  Front Physiol       Date:  2020-09-04       Impact factor: 4.566

10.  SERCA2a stimulation by istaroxime improves intracellular Ca2+ handling and diastolic dysfunction in a model of diabetic cardiomyopathy.

Authors:  Eleonora Torre; Martina Arici; Alessandra Maria Lodrini; Mara Ferrandi; Paolo Barassi; Shih-Che Hsu; Gwo-Jyh Chang; Elisabetta Boz; Emanuela Sala; Sara Vagni; Claudia Altomare; Gaspare Mostacciuolo; Claudio Bussadori; Patrizia Ferrari; Giuseppe Bianchi; Marcella Rocchetti
Journal:  Cardiovasc Res       Date:  2022-03-16       Impact factor: 10.787

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.